-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SSAA09E2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/883944-52-3.gif)
| Category | SARS-CoV |
| CAS | 883944-52-3 |
| Description | SSAA09E2 is a SARS-CoV inhibitor that acts by blocking early interactions of SARS-S with the receptor for SARS-CoV, angiotensin converting enzyme 2 (ACE2). |
Product Information
| Synonyms | SSAA-09E2; SSAA 09E2 |
| IUPAC Name | N-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-1,2-oxazole-5-carboxamide |
| Molecular Weight | 300.36 |
| Molecular Formula | C16H20N4O2 |
| Canonical SMILES | CN1CCN(CC1)C2=CC=C(C=C2)CNC(=O)C3=CC=NO3 |
| InChI | InChI=1S/C16H20N4O2/c1-19-8-10-20(11-9-19)14-4-2-13(3-5-14)12-17-16(21)15-6-7-18-22-15/h2-7H,8-12H2,1H3,(H,17,21) |
| InChIKey | OMRXBNSVRJWWAZ-UHFFFAOYSA-N |
| Purity | >98% |
| Solubility | Soluble in DMSO. |
| Appearance | Solid Powder |
| Storage | Store at -20°C |
| Complexity | 363 |
| Exact Mass | 300.15862589 |
| Target | SARS-CoV |
| XLogP3-AA | 1.4 |
